XR 5000

Drug Profile

XR 5000

Alternative Names: AC; Acridine carboxamide; DACA; NSC 601316; SN 22995

Latest Information Update: 26 Feb 2001

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Auckland Cancer Society Research Centre
  • Developer Cancer Research UK; Xenova Group
  • Class Antineoplastics
  • Mechanism of Action DNA topoisomerase I inhibitors; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Colorectal cancer; Glioblastoma; Malignant melanoma; Non-small cell lung cancer; Ovarian cancer

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 26 Feb 2001 Discontinued-II for Glioblastoma in Europe (Infusion)
  • 26 Feb 2001 Discontinued-II for Non-small cell lung cancer in Europe (Infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top